Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure

    NEXT STORY
    Oncology Venture increases its ownership in dovitinib
    PREV STORY
    The Three Strategies of Individual Patient Engagement
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Diabetic Ulcer Treatment Market to Reach $13.22 Billion by 2026; Increasing Investment in Product R&D to Aid Growth, says Fortune Business Insights™

    author_avatar
    NASDAQ Market News

    NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING

    author_avatar
    NASDAQ Market News

    Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018

    NEWTOWN, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a ...

    author_avatar
    NASDAQ Market News